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Abstract
Background: Calls have been made for increased access to individual participant data (IPD) from clinical trials, to ensure that
complete evidence is available. However, despite the obvious benefits, progress towards this is frustratingly slow. In the
meantime, many systematic reviews have already collected IPD from clinical trials. We propose that a central repository for
these IPD should be established to ensure that these datasets are safeguarded and made available for use by others,
building on the strengths and advantages of the collaborative groups that have been brought together in developing the
datasets.
Objective: Evaluate the level of support, and identify major issues, for establishing a central repository of IPD.
Design: On-line survey with email reminders.
Participants: 71 reviewers affiliated with the Cochrane Collaboration’s IPD Meta-analysis Methods Group were invited to
participate.
Results: 30 (42%) invitees responded: 28 (93%) had been involved in an IPD review and 24 (80%) had been involved in a
randomised trial. 25 (83%) agreed that a central repository was a good idea and 25 (83%) agreed that they would provide
their IPD for central storage. Several benefits of a central repository were noted: safeguarding and standardisation of data,
increased efficiency of IPD meta-analyses, knowledge advancement, and facilitating future clinical, and methodological
research. The main concerns were gaining permission from trial data owners, uncertainty about the purpose of the
repository, potential resource implications, and increased workload for IPD reviewers. Restricted access requiring approval,
data security, anonymisation of data, and oversight committees were highlighted as issues under governance of the
repository.
Conclusion: There is support in this community of IPD reviewers, many of whom are also involved in clinical trials, for
storing IPD in a central repository. Results from this survey are informing further work on developing a repository of IPD
which is currently underway by our group.
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Introduction
Data that are collected on individuals who participate in a
clinical trial are traditionally kept by the trial’s research group or
sponsor, with research utilising these data usually being under-
taken by the same group. An increasing number of appeals have
been made for these data to be made more widely available,
accompanied by relevant documentation such as the protocol and
any amendments (see references [1],[2],[3],[4] for example), to
enable more complete and unbiased evidence syntheses, facilitate
the identification of factors to personalise the delivery of medicine,
and accelerate methodological research in clinical trials and
evidence synthesis. Gøtzsche [2] describes a selection of examples,
including the recent Tamiflu experience, that demonstrate the
need for increased transparency and wider access to clinical trial
data and documentation.
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The BMJ recently announced a new policy on sharing clinical
trial data which states that ‘‘from Jan 2013 trials of drugs and
medical devices will be considered for publication only if the
authors commit to making the relevant anonymised patient level
data available on reasonable request’’ [5]. In 2011, The Cochrane
Collaboration published a statement [6], which has recently been
revised, supporting free access to all data from all clinical trials,
and other journals have also issued data sharing policies [7],[8].
For example, PLoS journals [9] actively promote the linking of
publications to ‘Dryad’ [10], an open access repository of data
underlying peer-reviewed articles. The ‘All Trials’ initiative [11] is
campaigning for the publication of all results from all clinical trials
on all treatments, and their on-line petition had received more
than 58,000 signatures by April 2014 from representatives of
public funding bodies, journals, Royal Colleges, evidence based
medicine organisations, charities, and pharmaceutical companies.
The European Medicines Agency have issued their data sharing
views [12] and are currently engaging in a consultation process,
which includes pharmaceutical companies and academia, to
develop an approach for sharing the individual participant data
collected in trials used to support marketing approval applications.
Further, public funding bodies such as the UK’s Medical Research
Council [13] and the National Institutes of Health in the USA [14]
have specific data sharing policies that theoretically supports the
open transfer of data collected on individual participants in the
trials that they fund.
In anonline survey of 317 corresponding authors of clinical trials
who had published their trials across six high impact journals in
2010 or 2011 [15], nearly three quarters of the respondents
thought that sharing clinical trial data in repositories, or on specific
request, should be a requirement. However, despite the wide
support for sharing clinical trial data, there are significant
challenges, and obtaining access to data is not as straightforward
as it should be. For example, a survey by Savage [16] found that
only 1 of 10 trials that had pledged an open data policy in their
funding application actually provided the individual participant
data when requested. Some of the challenges that have been
identified previously include patient privacy issues, pharmaceutical
companies’ reluctance to share data with competitors, academic
investigators protecting their publication potential, and a lack of
resource to organise the data to be shared [17]. Despite these
concerns, some trialists do make their data publicly available [18],
and there are recent initiatives to develop repositories for trial data
[10,19] and standards for the public disclosure of data [20].
One advantage of central repositories of clinical trial data would
be to accelerate the production of systematic reviews and meta-
analysis of individual participant data (IPD), which are regarded as
more reliable than other forms of systematic review [21]. The IPD
approach to systematic reviews offers the opportunity to identify
unpublished trials through collaboration with the original
researchers, incorporate additional follow-up which can lead to
improving the reliability of effect estimates, reduce bias by
analysing on an intention to treat basis, minimise the possibility
of within study selective reporting, standardise outcome definition
across trials, and increase the potential to investigate subgroup
effects. The main disadvantages of IPD reviews are that they
require more resources, and rely on being able to gain access to
participant level data from the included clinical trials to minimise
the potential for data availability bias [22]. However, there are
many examples in the literature of systematic reviews based on
IPD and their number has increased from a few publications per
year in the early 1990s to around 50 per year from 2005 [21]. IPD
reviews often only address the main treatment efficacy question
but many more questions could be explored using these datasets.
For example, exploring multiple prognostic factors, assessing the
effect of patient-level covariates (e.g. age, dose of drug,
menopausal status) on treatment benefits and harms, and
enhancing the ability to make reliable indirect comparisons and
network analysis (see [23], [24,25] for example) which should be
considered as the bedrock for decisions when several treatments
are available [26]. Since the IPD datasets have already taken a
long time to prepare, with many issues identified and discussed
with original researchers to reach the final ‘clean’ data used for re-
analysis, there is a strong argument that these data should also be
made available for research purposes, to maximise their value and
research potential.
The Cochrane Collaboration IPD Meta-analysis Methods
Group comprises people who are interested in the conduct of
systematic reviews that include IPD, many of whom have
participated in this type of research. We present results from a
survey of all members of the Methods Group to explore their
willingness to provide anonymised IPD (with the permission of the
original researchers, as necessary) from previously conducted
systematic reviews for central storage and management, to be
made available for research projects, and to seek their opinions on
the practicalities of doing so.
Methods
A pilot questionnaire was developed by the research team and
tested using a group of IPD reviewers attending a contributors’
meeting of The Cochrane Collaboration. Feedback from this pilot
phase was incorporated into an amended on-line questionnaire,
which was developed using Surveygizmo [27]. A brief synopsis and
hyperlink to the survey was emailed to all 71 members of the
Cochrane IPD Meta-analysis Methods Group in March 2011,
with three e-mail reminders sent to non-responders during April
and May 2011. The questionnaire included 16 questions
(Appendix S1) which would take an average of 10 minutes to
complete. Ethical approval was not required from the University
of Liverpool Research Ethics Committee as this project was
considered a survey of current practice. Due to the online format
of the survey, completion of the questionnaire was regarded as
consent to participate and all data were anonymised. Free text
responses were categorised by the lead author. All responses were
summarised as percentages, with corresponding 95% confidence
interval (Wilson score method).
Results
Of the 71 people invited to participate, 40 responded (Figure 1).
However, 10 of these responses were partial without any useable
data and, therefore, the summary of results is restricted to the
remaining 30 (response rate: 42%) complete responders.
Twenty two (73%) responders were from the United Kingdom,
6 (20%) from other European countries, 1 (3%) from Australia and
1 (3%) from Canada. The percentage of responders from each
country is comparable to the percentage breakdown across the
whole group of 71 contacts (60% UK; 28% other European
countries; 2% Australia; 5% Canada; 5% other). Most of the
responders had been involved in at least one IPD review (28 (93%))
and at least one randomised trial (24(80%)). Both IPD review and
randomised trial involvement had been across a wide range of
health areas including oncology, obstetrics and gynaecology,
epilepsy, and surgery. Responders with randomised trial experi-
ence recorded a variety of roles within the trials, most as
statisticians (9 (30%)), trial managers (6 (20%)) or investigators (4
(13%)). Responders’ roles within systematic reviews also varied,
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Figure 1. Flow diagram of survey responses.
doi:10.1371/journal.pone.0097886.g001
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with most stating that they had led, or contributed to the majority
of the review.
Twenty five (83%, 95% CI: 66% to 93%) of the complete
responders agreed that a central repository for IPD was a good
idea (Figure 1). Among these 25 responders, the most commonly
cited positive reasons (multiple reasons identified by some
responders) were the need to safeguard and standardise data (9
(36%, 95%CI: 20% to 55%)), increase efficiency of undertaking
IPD meta-analysis (5 (20%, 95% CI: 9% to 39%)), allow future
research and knowledge advancement (5 (20%, 95% CI: 9% to
39%)), and facilitate methodological studies (5 (20%, 95% CI: 9%
to 39%)). Some negative reasons were also highlighted by the 25
responders (Figure 1). Five of the 30 (17%, 95% CI: 7% to 34%)
responders did not agree that a central repository for IPD was a
good idea. For these 5, uncertainty of the purpose of such a
repository (4 (80%, 95% CI: 38% to 96%)), barriers (2 (40%, 95%
CI: 12 to 77%)), effort for the IPD reviewer (2 (40%, 95% CI: 12
to 77%)), and data release issues (2 (40%, 95% CI: 12 to 77%))
were the most common reasons for the negative response
(Figure 1).
Unsurprisingly, most of the positive responders (24/25) would
be willing to store their IPD in a central repository, whilst most of
the negative responders (4/5) would not (Figure 1). Amongst the
25 willing responders, the most common requirements for
depositing IPD in the repository were around gaining data
approval (11 (44%, 95% CI: 27% to 63%)) and appropriate
acknowledgement (6 (24%, 95% CI: 12% to 43%)) for the source
of the IPD. The need to involve investigators in the process (4
(16%, 95% CI: 6% to 35%)), reassurances of who would access the
data (3 (12%, 95% CI: 4% to 30%)), and the need for a scientific
committee to review requests for data (3 (12%, 95% CI: 4% to
30%)) were also noted by more than one responder. The five
responders who said that they would not store their data in a
central repository noted that data approval would be difficult (3
(60%, 95% CI: 23% to 88%)) or that they could not store the data
because it is not theirs (2 (40%, 95% CI: 12% to77%)).
Over a third of the 30 responders were uncertain about the data
format and governance arrangements for a central repository
(Table 1). The most common suggestion (9 (30%, 95%CI: 17% to
48%) responders) was for a simple data format to allow for
different data types, e.g. comma separated variables (csv) or an
Excel spreadsheet. Two (7%, 95% CI: 2 to 21%) responders noted
the importance of password protection, 2 (7%, 95% CI: 2 to 21%)
suggested that only a minimum dataset should be stored, and two
(7%, 95% CI: 2 to 21%) suggested that a specific format for the
data was not important if appropriate documentation accompa-
nied the data (Table 1). When asked what governance arrange-
ments would be expected, 10 (33%, 95%CI: 19% to 51%)
responders stated that access to data should be restricted and
require approval, 6 (20%, 95% CI: 10% to 37%) noted the
importance of data security, 4 (13%, 95% CI: 5% to 30%)
expected the use of an oversight committee, 4 (13%, 95% CI: 5%
to 30%) would expect appropriate recognition for data owners,
and 3 (10%, 95% CI: 3 to 26%) raised the issue of making sure
that data were anonymised (Table 1).
We also asked for specific advantages of a central repository,
and obstacles (question 15 and 16). Some of these responses
overlap with previous questions but we report them separately
here for completeness (Table 2). The main reported advantages
were to improve methodological research (7 (23%, 95% CI: 12%
to 41%) responders), increase research using the data (5 (17%,
95% CI: 7% to 34%)), facilitate undertaking or updating IPD
reviews (5 (17%, 95% CI: 7% to 34%)), and to safeguard the data
(5 (17%, 95% CI: 7% to 34%)). The ability to undertake analyses
across conditions or treatments, explore treatment effect modifiers,
improve the quality of IPD reviews, increase the number of IPD
reviews, increase collaboration, and transparency of research, were
other noted advantages (Table 2). The main perceived obstacle
was difficulty gaining permission from data owners, which was
mentioned by 18 (60%, 95% CI: 42% to 75%) responders. Seven
(23%, 95% CI: 12% to 41%) responders suggested that developing
and maintaining the repository would be resource intensive and 3
(10%, 95% CI: 3 to 26%) felt that communicating the purpose of
the repository could be an obstacle. Lack of acceptance from IPD
reviewers if procedures for recognition were not in place, data
coding issues, trust, difficulties reaching agreement on how data
should be stored, and ethical issues, were other obstacles that were
raised (Table 2).
Discussion
In this online survey of the members of the Cochrane
Collaboration IPD Meta-analysis Methods Group, over 80% of
responders agreed with the principle of creating a central
repository for individual participant level data from randomised
trials which had been collected for completed systematic reviews,
with the same number of responders stating their willingness to
share their IPD data sets. This survey complements the work by
Rathi et al [15] which also showed strong support for data sharing:
more than 70% of the corresponding authors of clinical trials
published in a sample of high impact medical journals supported
sharing de-identified data through data repositories or in response
to individual requests. One of the strengths of our survey is that the
majority of responders had been involved in both randomised
trials and IPD reviews. They therefore represent the views of
researchers who have been involved both in collecting and
analysing data in individual studies (i.e. people who would deposit
data from randomised trials) and in collecting and re-analysing
data for evidence synthesis (i.e. end-users who would use the
deposited data for new analyses). To our knowledge, this is the first
survey to capture opinions about data sharing from this group of
researchers who are able to provide their personal, all round view.
Some valid concerns were raised about the purpose, structure,
governance arrangements and resource requirements for estab-
lishing and maintaining a central repository. The success of such
an initiative would be fully dependent on gaining permission from
the original clinical trialists who had provided their IPD for the
systematic review. A minority of responders felt that this barrier,
along with the increased effort and potential lack of appropriate
recognition for the IPD reviewers, would preclude the success of
such a facility. However, given that the clinical trialists have
already agreed to share their data by contributing to the IPD
review, they might be particularly amenable to the concept of a
centralised repository. Therefore, as long as the appropriate
governance and security measures are in place to protect and
release the data to researchers, and as long as clinical trialists’
concerns are addressed adequately (for example, through appro-
priate recognition to contributors), we do not believe that gaining
permission from trialists will be a considerable barrier. Indeed, if it
is not possible to gain permission from this group of trialists who
are already engaged with data sharing for the purpose of IPD
reviews, it is difficult to see how some of the data sharing visions,
including those from an industry perspective that have been
expressed in the literature recently(29), would ever be realised.
Nevertheless, these potential barriers are worth exploring further.
As an example of how better use could be made of IPD, authors of
this paper have used the IPD from randomised trials of anti-
epileptic drug trials in the late 1990s to (i) undertake a suite of
Sharing Individual Participant Data from Clinical Trials
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head-to-head comparative meta-analyses [28–33], (ii) develop and
apply methodology for a network analysis of IPD [23] which led to
the estimation of comparative treatment effects that were not
available from head-to-head randomised trials, (iii) inform the
design of the largest ever trial in epilepsy [34,35], (iv) contribute to
the development of National Institute for Health and Clinical
Excellence (NICE) guidance on epilepsy [36], (v) explore
treatment effect modifiers [37] and (vi) as case studies to facilitate
the development of methodological research in meta-analysis
[24,25,38–42].
The issue of data sharing is topical at the moment, with several
initiatives underway to make data from clinical trials more
accessible. Of particular relevance is the European Medicines
Agency’s (EMA) draft policy on proactive access to clinical-trial
data which was published in June 2013 for public consultation
[43]. The policy, which has been welcomed by the research
community, describes the EMA’s plans to make future clinical trial
data, including IPD, which is submitted to the EMA, available to
external parties according to differing levels of control. There are
some concerns and ethical implications that require further
discussion in the clinical trials community and beyond but we
hope that access to clinical trial data will become easier, and that
the associated benefits will be realised. In the meantime, the
appropriate storage and restricted release of IPD collected for
systematic reviews is a logical and worthwhile venture and we are
exploring issues of data release, participant confidentiality and
governance of a central repository, which will then be developed
and piloted. These plans will contribute to other ongoing work in
the area of open access clinical trial data.
Limitations of the study
This cross-sectional survey is limited to members of the
Cochrane IPD Meta-analysis Methods Group and may not
necessarily capture the opinion of IPD reviewers outside the
Cochrane Collaboration. We do know that the majority of
members are from non-commercial research institutes as it is these
that are predominantly involved with IPD research. Therefore, it
is possible that pharmaceutical industry representatives responsible
for running clinical trials would have a different opinion to those
expressed in this survey.
Table 1. Views regarding the format of data and governance arrangements for a central repository of IPD.
Number of responders (% and 95% CI)
Q13. What format would you recommend for storing and accessing the IPD?1
simple format to allow for different data types eg csv, excel 9 (30 (17 to 48))
password protected 2 (7 (2 to 21))
minimum dataset 2 (7 (2 to 21))
format not important 2 (7 (2 to 21)
SPSS 2 (7 (2 to 21))
Oracle, Stata, xml 1 (3 (0 to 17))
well documented data base including documentation for all errors and limitations 1 (3 (0 to 17))
not central storage but full description of data and where to access 1 (3 (0 to 17))
SAS 1 (3 (0 to 17))
relational database, in legacy format with metadata/documentation 1 (3 (0 to 17))
not sure/not answered 11 (37 (22 to 54))
Q14. What governance arrangements would you expect?2
restricted access requiring approval 10 (33 (19 to 51))
data security 6 (20 (10 to 37))
oversight committee 4 (13 (5 to 30))
recognition for data owners 4 (13 (5 to 30))
anonymised data 3 (10 (3 to 26))
clearly stated publication policy 2 (7 (2 to 21))
clear process required 2 (7 (2 to 21))
permission from data owners 2 (7 (2 to 21))
approval granted by data depositor 1 (3 (0 to 17))
as advised by QA 1 (3 (0 to 17))
all statutory requirements 1 (3 (0 to 17))
recognition for IPD principal investigator 1 (3 (0 to 17))
recognition for repository owners 1 (3 (0 to 17))
no governance required as data should be freely available 1 (3 (0 to 17))
not sure/not answered 11 (37 (22 to 54))
Responders could provide more than one reason so the numbers do not add to 30.
13 responders recorded two formats.
28 responders recorded two governance issues, 1 responder recorded three governance issues, 2 responders recorded four governance issues, 1 responder recorded
five governance issues.
doi:10.1371/journal.pone.0097886.t001
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Although the survey was kept as simple as possible, required
10 minutes to complete, and was followed by three email
reminders, only 42% of individuals we invited provided useable
responses. Although disappointing, this is a typical response rate
for online surveys [44] and is similar to the response rate of 46%
achieved by the online survey of clinical trial data sharing by Rathi
et al [15], which was despite their use of telephone reminders and
the opportunity for responders to be entered into a prize draw to
win one of five $100 gift certificates. Furthermore, when we
compared the country of residence for responders against the
country of residence for the full list of 71 members, this suggested
that responders were a representative group. In addition, as the
methods group is open for anyone to join it is entirely possible that
some members are not actively involved with IPD research but
may have at some time in the past expressed an interest in the
topic. Members who have a strong opinion in favour or against the
principle of data sharing are likely to have responded to ensure
that their voice was heard. Therefore, we believe that non-
responders were most likely to be those without a strong view on
the subject, or those not actively involved with IPD meta-analysis
research. Unfortunately, we have very little information regarding
members’ characteristics to verify this as these data are not
routinely collected by the Cochrane methods group. We consider
that the 30 responses are sufficient to provide initial discussion
points on which to base our further work. It is also reassuring that
our survey results are in keeping with a previous survey of clinical
trialists [15].
The survey was originally launched in March 2011 and we
recognise that responders’ opinions may have changed. However,
in response to a short internal consultation process to finalise the
revised Cochrane Collaboration statement on access to trial data,
a recent e-mail discussion within the Cochrane IPD Meta-analysis
Methods Group identified very similar issues to those raised in our
survey with the most contentious issue being whether data should
Table 2. Views regarding the main advantages and main obstacles for a central repository of IPD.
Number of responders (% and 95% CI)
Q15. What do you expect to be the main advantages of creating a repository?1
improving methodological research 7 (23 (12 to 41))
increase research using the data 5 (17 (7 to 34))
facilitate undertaking/updating of IPD reviews 5 (17 (7 to 34))
safeguard the data 5 (17 (7 to 34))
larger analyses across conditions or treatments 2 (7 (2 to 21))
Explore treatment effect modifiers 2 (7 (2 to 21))
sharing data 2 (7 (2 to 21))
improving quality of IPD reviews 2 (7 (2 to 21))
transparency of research 2 (7 (2 to 21))
increase collaboration between research groups 2 (7 (2 to 21))
increase number of IPD reviews 2 (7 (2 to 21))
extend repository to individual clinical trials 1 (3 (0 to 17))
sharing data 1 (3 (0 to 17))
not sure/not answered/‘see previous’ 8 (27 (14 to 44))
Q16. What do you expect to be the main obstacles to creating a repository?2
difficulties gaining permission from data owners 18 (60 (42 to 75))
resource intensive to establish and maintain 7 (23 (12 to 41))
communicating the purpose of the repository 3 (10 (3 to 26))
lack of buy-in from IPD reviewers if procedures for recognition not in place 2 (7 (2 to 21))
data coding issues 2 (7 (2 to 21))
Trust 2 (7 (2 to 21))
difficulties getting agreement on how data should be stored 2 (7 (2 to 21))
ethical issues 2 (7 (2 to 21))
practical issues 1 (3 (0 to 17))
legal issues 1 (3 (0 to 17))
difficulties ensuring appropriate recognition to data owners 1 (3 (0 to 17))
not knowing the purpose 1 (3 (0 to 17))
ensuring data owners are involved with process 1 (3 (0 to 17))
governance issues 1 (3 (0 to 17))
not sure/not answered/‘see previous’ 3 (10 (3 to 26))
Responders could provide more than one reason so the numbers do not add to 30.
18 responders recorded two advantages, 2 responders recorded three advantages, 1 responder recorded five advantages.
28 responders recorded two obstacles, 3 responders recorded three obstacles, 1 responder recorded four obstacles.
doi:10.1371/journal.pone.0097886.t002
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be ‘completely open access’ or ‘restricted’ in some way. The topic
of data sharing is incredibly fast moving with initiatives evolving
very quickly. We believe that results from this survey, alongside
other similar work that has been published can help to inform
future research in this area. The questionnaire used open text
fields, which were then categorised for presentation of results. The
percentage of responders in each category should be interpreted
cautiously. For example, only 3 (10%, 95% CI: 3 to 26%)
responders specifically mentioned ‘anonymised data’ when asked
about governance arrangements for the repository. However, it is
highly likely that most responders would agree that anonymised
data would be a critical element of this repository given that IPD
meta-analyses are usually undertaken only with anonymised data.
Therefore, the IPD reviewers may have assumed that this would
also be the case within the repository, or it may be that they did
not consider this issue to be relevant to the question about
governance.
Conclusions
Sharing clinical trial data is essential to accelerate research and
increase transparency in trials, so that evidence-based decisions for
patient care are informed by the highest quality and most
complete data. Significant steps towards this ideal are already
being made by funding bodies, regulatory authorities, pharma-
ceutical companies and medical journals which should strengthen
future research. In the meantime, we need to consider how best to
maximise the availability and impact of IPD that have already
been collected for IPD systematic reviews and meta-analyses. If the
emerging view is that providing IPD from individual trials should
be an obligation, then it would follow that IPD from existing and
future IPD meta-analyses should also be made available. A central
repository for storing this IPD would be valuable and this survey
has demonstrated support for this amongst IPD reviewers. Further
research is now underway in regard to how this could be
implemented and evaluated.
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